Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary analysis of a randomized, split-body, single blinded, placebo controlled clinical trial’” - 19/09/18
Doi : 10.1016/j.jaad.2018.05.1238
Samir Arbache, MD a, ⁎ 
, Nilceo Schwery Michalany, MD b, Sergio Henrique Hirata, MD, PhD c
, Nilceo Schwery Michalany, MD b, Sergio Henrique Hirata, MD, PhD c a PhD program in Evidence-Based Medicine of the São Paulo State School of Medicine, Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP)/SP, Brazil
b Department of Pathology, São Paulo State School of Medicine, Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP)/SP, Brazil
c Department of Dermatology, São Paulo State School of Medicine, Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP)/SP, Brazil
∗Correspondence to: Samir Arbache, MD, Rua Coronel Madeira, 45 Centro, São José dos Campos, Estado de São Paulo, Brazil, Cep 12245-760Rua Coronel Madeira45 Centro, São José dos CamposEstado de São PauloCep 12245-760Brazil
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Arbache is owner of Traderm, a profit-oriented business that sells tattoo machines and cartridges for tattoo machines for doctors, and owner of Sempre Bella, a medical education company. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 4
P. e81-e82 - octobre 2018 Retour au numéro
Article précédent
- Comment on “Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary analysis of a randomized, split-body, single blinded, placebo controlled clinical trial”
- Carlos Gustavo Wambier
- Comment on “Drug survival of apremilast for psoriasis in a real-world setting”
- Jorge Santos-Juanes, Lucía Velasco, Pablo Munguía-Calzada, Ana Lozano, Santiago Gómez-Díez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?